Abstract: A method for preparing a coordination complex of an isonitrile ligand and a radioisotope of Tc, Ru, Co, Pt, Re, Os, Ir, W, Re, Cr, Mo, Mn, Ni, Rh, Nb and Ta from a non-radioactive metal adduct of the isonitrile.

Abstract: A liquid crystal compound represented by formula: ##STR1## wherein R.sub.1 represents a straight chain alkyl group having from 4 to 18 carbon atoms; R.sub.2 represents a straight chain alkyl group having from 2 to 6 carbon atoms or a branched alkyl group having from 3 to 6 atoms and having a methyl group as a side chain; and m and n each represents 1 or 2, is disclosed.The liquid crystal compound of formula (I) is optically and electrically stable and exhibits fast electro-optical switching in image display.

Abstract: Dichroic coloring agents which have a blue to blue-violet hue and have not been used to date for liquid crystal displays are disclosed. These coloring agents are represented by the following formula: ##STR1## wherein X is S or NH; R.sub.1 is a hydrogen atom, halogen atom, alkyl group or alkoxy group; and R.sub.2 is a hydrogen atom, alkyl group, aryl group or aralkyl group.

Abstract: The optically active compounds of the formula: ##STR1## wherein R.sup.1 is an alkyl or an alkyloxy group having a carbon number of 1-18, R.sup.2 is an alkyl group having a carbon number of 1-18, and A is a biphenyl group or a biphenyl group having a halogen atom or a cyano group are provided.The optically active compounds are useful for liquid crystal elements, especially for components of ferroelectric liquid crystal mixtures inducing high value of spontaneous polarization.

Abstract: An optically active lactic acid derivative represented by the following formula (I): ##STR1## wherein R represents a linear, branched or cyclic saturated or unsaturated hydrocarbon group having 1 to 18 carbon atoms; C* represents an asymmetric carbon atom; l is 0 or 1; m is 1 or 2; A represents a group selected from the following groups (a) and (b):(a) hydroxyl group, halogen, benzyloxy group, phenoxy group, toluenesulfonic acid group, acetyloxy group trifluoroacetyloxy group; ##STR2## (wherein R' is an alkyl group or alkoxy group having 4 to 18 carbon atoms, n is 0 or 1, ##STR3## with proviso that when A is selected from the group in the above group (a), l is 1 and m is 1 or 2; and when A is selected from the groups in the above group (b), m=n=1 when l is 0, or m and n are 0, 1 or 2 and m+n is 1 or 2 when l is 1, and ##STR4##

Abstract: An optically active lactic acid derivative represented by the following formula (Ia) or (Ib): ##STR1## wherein R is a linear, branched or cyclic saturated or unsaturated hydrocarbon group having 1-16 carbon atoms,R.sup.1 is an alkyl group having 4-16 carbon atoms,m and n are respectively 1 or 2,k is 0 or 1, andC* is an asymmetric carbon atom.A liquid crystal composition containing the lactic acid derivative and a liquid crystal device using the liquid crystal composition are also disclosed.

Abstract: Disclosed is an optically active cyclopropane compound represented by the formula (1): ##STR1## wherein R is an alkyl or cycloalkyl group, n is 0 or 1, Y.sup.4 is --CO.sub.2 CH.sub.2 --, --OCO-- or --OCH.sub.2 --, Y.sup.1, Y.sup.2 and Y.sup.3 independently represent --CO.sub.2 --, --OCO--, --O--, a direct bond or --CH.sub.2 O--, Z.sup.1, Z.sup.2, and Z.sup.3 independently represent ##STR2## A.sup.1, A.sup.2 and A.sup.3 independently represent fluorine, bromine, chlorine, a cyano group or hydrogen, and the mark ##STR3## indicates an asymmetric carbon atom. The optically active cyclopropane compound includes a compound which exhibits a ferroelectric liquid crystalline characteristic, and a compound which does not exhibit a ferroelectric liquid characteristic when used alone, but, can be used as a constituent of a ferroelectric liquid crystal composition.

Abstract: A non-radioactive labeling composition for preparation of a technetium 99m-labeled radioactive diagnostic agent, which comprises a small amount of a lyophilized product obtained from a stannous chloride solution having a high concentration of stannous chloride charged in a container.

Abstract: The novel compounds are chiral esters of .alpha.-substituted phenylalkanoic acids and mesogenic hydroxy compounds, the symbols in the general formula (I) ##STR1## being defined as follows: MO=molecular radical of a mesogenic hydroxy compound MOH after removal of one H, the radical MO being expressed by the general formula (II)R.sup.2 --(A.sup.1).sub.n1 --(B--).sub.n2 (A.sup.2).sub.n3 --O (II)whereR.sup.2 =straight-chain or branched (C.sub.1 -C.sub.12)-alkyl, it being possible for one or two non-adjacent CH.sub.2 groups to be replaced by O and/or S atoms, or, if n1=1, also F, Cl, Br, CN or CF.sub.3,A.sup.1, A.sup.2 =independently of one another 1,4-phenylene, diazine-2,5-diyl, diazine-3,6-diyl, 1,4-cyclohexylene, 1,3-dioxane-2,5-diyl, 1,3-dithiane-2,5-diyl or 1,4-bicyclo(2,2,2)octylene, it being possible for these groups also to be at least monosubstituted by F, Cl, Br, CN, CF.sub.3 and/or (C.sub.1 -C.sub.12)-alkyl (one or two non-adjacent CH.sub.

Abstract: Polymers contain, as mesogenic groups, groups which produce a discotic phase, and furthermore can contain pleochroic dyes.The novel polymers possess novel properties, and combinations of properties, which the conventional polymers which form liquid-crystalline phases do not possess.The polymers can be used in electro-optical displays, in storage elements, as electrically or photo-electrically conductive polymers and as strain sensors.

Abstract: An optically active ester compound is provided represented by the following general formula: ##STR1## wherein R.sub.1 is a normal alkyl group having from 6 to 18 carbon atoms; m is zero or one, n is zero or one, and m+n is one or two; X is --CO--O-- or --O--CO--; p is 3 to 6; Y is a hydrogen atom or chlorine atom; R.sub.2 is hydrogen or a normal alkyl group having from 1 to 11 carbon atoms but may be a hydrogen atom only when Y is a chlorine atom; and *C represents an asymmetric carbon atom. The ester compound of the present invention is useful as a ferroelectric liquid crystal compound.

Abstract: There are disclosed liposomes to which are linked agents which are capable of binding an anti-tumor antibody. The liposomes are useful in the detection and treatment of tumors by reason of their ability to remove non-specifically distributed anti-tumor antibodies from vascular and other extra-cellular spaces.

Abstract: Disclosed is a method for measuring the effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of the mammal but not to external cellular components, wherein the monoclonal antibody is labeled; contacting the labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo, and determining the effectiveness of the therapy by measuring the binding of the labeled antibody to the internal cellular component. The internal cellular component is preferably insoluble intracellular antigen, and the label is preferably a radionuclide, a radiopaque material, or a magnetic resonance-enhancing material. Also disclosed is a method whereby the antibody to insoluble intracellular antigen is conjugated to an antineoplastic agent, so that upon administration of the antibody-antineoplastic agent conjugate, antineoplastic agent may be delivered to the tumor.

Abstract: Mixtures of liquid crystal compounds from among different classes of liquid crystal ester compounds are disclosed. The mixtures exhibit freezing points substantially lower than the freezing point of either ester compound alone, so as to provide a substantially improved (widened) smectic C mesomorphic temperature range and protection against freezing or crystallization of liquid crystal material over a range of temperatures at which an electrooptic display device would typically be operated.

Abstract: Novel lactic acid derivatives which may be used as a component of a ferroelectric smectic liquid crystal mixture, which derivatives have the general formula: ##STR1## in which R.sub.1 is alkyl or alkoxy and R.sub.2 is alkyl. Liquid crystalline compositions containing these compounds are also described.

Abstract: Compounds of the formula I:R+[.sup.99m TcNX.sub.4 ]- Iwherein R+ represents a cation and X represents a halo group, are prepared by reaction with an azide compound in the presence of a hydrohalic acid. The compounds are useful in production of .sup.99m Tc-labelled radio- pharmaceuticals by reaction with ligands and monoclonal antibodies or antibody fractions.

Abstract: A novel diagnostic procedure for the in vivo clinical evaluation of gastrointestinal ulcer disease and other diseases associated with loss of mucosal integrity in humans which comprises the oral administration of an effective amount of radio-labeled sucralfate or derivative or precusor thereof or a water soluble, physiologically compatible radiolabeled salt of sucrose suflate to the human host, followed by scintigraphic imaging of the gastrointestinal area of interest with scintigraphic imaging equipment.A novel radiopharmaceutical composition comprising an aqueous solution or suspension containing an amount of a radio-labeled sucralfate or derivative or precursor thereof or a water soluble, physiologically compatible radiolabeled salt of sucrose sulfate for in vivo scintigraphic imaging of the gastrointestinal or other muscosal areas in humans.

Abstract: .sup.1/3 Holmium in a carrier metallic hydroxide aggregate is disclosed for the treatment of arthritis and, in particular, rheumatoid arthritis. The compound disclosed preferably has a particle size of 1 to 40 microns, Beta energy emissions in the range of 1.76-1.84 MeV, low levels of gamma ray emissions and a radioactive half-life of 26.8 hours. The preferred metallic hydroxide is selected from the group consisting of Ferric Hydroxide, Aluminum Hydroxide, Bismuth Hydroxide, Chromium Hydroxide, Cupric Hydroxide, Manganese Hydroxide and Stannous Hydroxide. Methods are also disclosed for the preparation of the compound, as well as for the methods of its administration to a patient in need thereof.

Abstract: A liquid crystal composition includes three liquid crystal materials, each selected from specified liquid crystal compounds. The composition has a low threshold voltage and a low viscosity.

Abstract: A method of treating an animal for the prevention or control of infestation by insects of the Order Diptera which comprises application to the animal of a compound of formula ##STR1##